Abstract
Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy with neurological disorder which incidence is relatively rare. Since the discovery of the ADAMTS 13 in 1996 and the changes in the treatment (plasma exchanges and rituximab), the prognosis of the TTP has considerably improved. We report the case of a 60-year-old man with a refractory TTP. The subsequent discovery of an epiglottis neoplasia and its treatment saved the patient.
Copyright © 2012. Published by Elsevier SAS.
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Squamous Cell / complications*
-
Carcinoma, Squamous Cell / diagnosis*
-
Carcinoma, Squamous Cell / drug therapy
-
Cisplatin / administration & dosage
-
Docetaxel
-
Epiglottis*
-
Fluorouracil / administration & dosage
-
Humans
-
Laryngeal Neoplasms / complications*
-
Laryngeal Neoplasms / diagnosis*
-
Laryngeal Neoplasms / drug therapy
-
Male
-
Middle Aged
-
Plasma Exchange
-
Plasmapheresis
-
Platelet Count
-
Purpura, Thrombotic Thrombocytopenic / complications*
-
Purpura, Thrombotic Thrombocytopenic / therapy
-
Rituximab
-
Taxoids / administration & dosage
-
Vitamin B 12 / therapeutic use
-
Vitamins / therapeutic use
Substances
-
Adrenal Cortex Hormones
-
Antibodies, Monoclonal, Murine-Derived
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents
-
Antineoplastic Agents, Phytogenic
-
Taxoids
-
Vitamins
-
Docetaxel
-
Rituximab
-
Vitamin B 12
-
Cisplatin
-
Fluorouracil